Search
Cue Biopharma Inc
CUEAdd to Watchlist
18.010USD
-1.830-9.22%
Close 11-05 16:00（ET）
130.75MMarket Cap
LossP/E TTM
Cue Biopharma Inc (CUE) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to Cue Biopharma Inc in the past month.
Strong Buy
1 Strong Buy
1 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
88.000USD+321.66%
CUE Analyst Recommendation Trends
In the current month, CUE has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CUE average Analyst price target in the last month is 88.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
1
1
0
0
0
0
0
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
1
1
1
1
1
1
CUE Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, CUE EPS is projected to reach -2.243 in FY2026Q3, following reported EPS of -24.140 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.10
-0.11
-1.69
-2.24
-1.76
Actual
0.44
-32.31
-24.14
--
--
Surprise
+539.80%
-29274.64%
-1328.39%
--
--
FAQs
What is Cue Biopharma Inc's expected revenue for the next quarter?
Cue Biopharma Inc's expected revenue is 1.03M.
What is Cue Biopharma Inc's price target?
Analysts forecast that Cue Biopharma Inc's price target is USD 88.00, with the highest forecast at USD 115.00 and the lowest forecast at USD 66.00.
How have Cue Biopharma IncCUE's recent earnings per share performed?
The market expectation was USD -24.14, while Cue Biopharma IncCUE's earnings per share (EPS) for the previous quarter was USD -32.31. EPS for the next quarter is expected at USD -2.24.
What is the analyst rating for Cue Biopharma Inc?
Based on the ratings of Cue Biopharma Inc's stock from 2 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.